Lead Product(s) : Galidesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioCryst Provides Update on Galidesivir Program
Details : Data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 22, 2020
Lead Product(s) : Galidesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galidesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19
Details : Galidesivir is an investigational broad-spectrum antiviral drug that was safe and well tolerated in previously reported Phase 1 trials in healthy subjects.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2020
Lead Product(s) : Galidesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galidesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : National Institutes of Health
Deal Size : $44.0 million
Deal Type : Funding
NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir
Details : The additional funds under these performance-based contracts support, The completion of parts 1 and 2 of an ongoing clinical trial of galidesivir in Brazil.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 31, 2020
Lead Product(s) : Galidesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : National Institutes of Health
Deal Size : $44.0 million
Deal Type : Funding
Lead Product(s) : Galidesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioCryst Pharmaceuticals Starts Clinical Trial of Anti-viral Drug
Details : Galidesivir has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including filoviruses and coronaviruses.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 01, 2020
Lead Product(s) : Galidesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galidesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 27, 2019
Lead Product(s) : Galidesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galidesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2019
Lead Product(s) : Galidesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Galidesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2014
Lead Product(s) : Galidesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : National Institute of Allergy and Infectious Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable